PR Newswire
BENSALEM, Pa.
,
July 1, 2021
/PRNewswire/ — Law Offices of
Howard G. Smith
reminds investors of the upcoming
August 9, 2021
deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ:
ACRX
) securities between
March 17, 2020
and
February 12, 2021
, inclusive (the “Class Period”).
Investors suffering losses on their AcelRx investments are encouraged to contact the Law Offices of
Howard G. Smith
to discuss their legal rights in this class action at 888-638-4847 or by email to
[email protected]
.
AcelRx is a pharmaceutical company that develops therapies for the treatment of acute pain. One of its lead product candidates is DSUVIA, which has been approved by the U.S. Food and Drug Administration (“FDA”) for the management of acute pain in adults that is severe enough to require an opioid analgesic in certified medically supervised healthcare settings.
On
February 16, 2021
, AcelRx disclosed that it had received a warning letter from the FDA concerning promotional claims for DSUVIA. Specifically, the FDA concluded that certain of AcelRx’s promotional communications “make false or misleading claims and representations about the risks and efficacy of DSUVIA,” and “[t]hus . . . misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative.”
On this news, AcelRx’s stock price fell
$0.21
per share, or 8.37%, to close at
$2.30
per share on
February 16, 2021
, thereby injuring investors.
The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA; (2) as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays; (3) the foregoing conduct subjected the Company to increased regulatory scrutiny and enforcement; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired AcelRx securities during the Class Period, you may move the Court no later than
August 9, 2021
to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact
Howard G. Smith, Esquire
, of Law Offices of
Howard G. Smith
, 3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania
19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to
[email protected]
, or visit our website at
www.howardsmithlaw.com
.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of
Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com
SOURCE Law Offices of
Howard G. Smith
